Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Arcutis today reported financial results for the quarter ended March 31, 2025, and provided a business update.
March 28, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.
October 25, 2023 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Report Third Quarter 2023 Financial Results

Arcutis will host a conference call and webcast at 8:30 a.m. ET on 11/3/2023 to report its third quarter financial results and provide a business update.
April 12, 2023 16:45 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present at Upcoming Investor Conference

WESTLAKE VILLAGE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
February 03, 2023 16:10 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
September 06, 2022 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
May 05, 2022 16:01 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and...
March 21, 2022 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Host Investor Day on March 28

WESTLAKE VILLAGE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
March 02, 2022 05:30 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present at Upcoming Investor Conference

WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
February 22, 2022 16:01 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment...